Kathmere Capital Management’s UroGen Pharma URGN Stock Holding History

Kathmere Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$271K	Buy	+7,360	New	+$199K	0.01%	548

Other funds holding URGN

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Kathmere Capital Management's URGN Position: Q2 2026 in Review

Kathmere Capital Management opened a new position in UroGen Pharma (URGN) in Q2 2026: 7,360 shares worth $271K. The stake represents 0.01% of the portfolio and ranks #548 among its holdings.

25 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Kathmere Capital Management held 7,360 shares of UroGen Pharma worth $271K as of Q2 2026.
UroGen Pharma was a new Kathmere Capital Management position in Q2 2026.
UroGen Pharma made up 0.01% of Kathmere Capital Management's portfolio in Q2 2026, its #548 holding.
25 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.